https://www.marketwatch.com/story/abbvie-umoja-biopharma-set-car-t-cell-therapies-collaboration-85409e2d
One of the largest pharma's in the world has signed a deal for exclusive option to license Umoja's CD19 directed in-situ generated CAR-T cell therapy candidates.
Preclinical mind you.
https://www.umoja-biopharma.com/our-pipeline/
Right team, right place and right time.
https://www.marketwatch.com/story/abbvie-umoja-biopharma-set-car-...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
-0.001(25.0%) |
Mkt cap ! $6.045M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.3¢ | $22.28K | 6.311M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 78 | 84735861 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 86304338 | 23 |
View Market Depth
| Last trade - 14.27pm 25/07/2025 (20 minute delay) ? |
| CHM (ASX) Chart |